We expect that an increasing emphasis on cost containment measures in the U.S. will continue to increase the pressure on pharmaceutical pricing.

filing / Apr 29, 2026 / receipt

International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or Israel.

filing / Apr 29, 2026 / receipt

appointed to serve as our Chief Executive Officer in January 2022 and has served as our Chief Financial Officer since April 2018 and previously served as our VP Finance from March 2018 until April 2018 and as our Controller from September 2017 to March 2018.

filing / Apr 29, 2026 / receipt

of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or

filing / Apr 29, 2026 / receipt

As part or independent of the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange, while

filing / Apr 29, 2026 / receipt

Any Restructuring Plan and possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses, regulatory approvals, receipt of any necessary consents, final approvals from our board of directors and shareholders and satisfaction of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo.

filing / Apr 29, 2026 / receipt